<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02377076</url>
  </required_header>
  <id_info>
    <org_study_id>526.005</org_study_id>
    <nct_id>NCT02377076</nct_id>
  </id_info>
  <brief_title>Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Vicosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do estado de Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of Vicosa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary calcium seems to act on glycemic control, favoring the prevention and treatment of
      type 2 diabetes mellitus (DM2). It is possible that calcium modulates gut microbiota and
      increase the integrity of the intestinal mucosa. This study aims to evaluate the effects of
      dietary calcium supplementation in permeability and intestinal microbiota in overweight type
      2 diabetics. This is a single-blind, randomized, placebo-controlled, crossover study.
      Patients (n=20) with low habitual calcium intake will be allocated in control group (CONTROL)
      or test group (DAIRY). Hypocaloric diets (restriction of 500 kcal / day) will be prescribed
      containing 800 mg of calcium from dietary sources / day. During intervention period, a
      beverage (shake) (CONTROL - without the addition of calcium sources or DAIRY - 700 mg of
      calcium as milk powder) will be ingested in the laboratory. Food intake, body composition
      (total body fat and fat free mass) and anthropometric measures (waist circumference,
      waist-hip ratio, waist-height, neck circumference and sagittal abdominal diameter) will be
      evaluated at baseline and at the 6th and 12th weeks. Physical activity level, gut
      permeability, gut microbiota, and biochemical parameters (parathyroid hormone, 25-dihydroxy
      vitamin D, calcium, fasting glucose, fasting insulin, fructosamine, hemoglobin, HbA1c, uric
      acid, triglycerides, cholesterol total and partial, lipopolysaccharide, inflammatory markers)
      will be evaluated at baseline and after 12 weeks. The statistical analysis will be performed
      with the use of SPSS software (SPSS Inc., Chicago, IL, 2008, version 17.0). Parametric or
      non-parametric tests will be applied, according to the distribution of variables (level of
      statistical significance of 5%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>DAIRY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary calcium supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary calcium supplementation</intervention_name>
    <description>Dietary calcium supplementation as milk powder</description>
    <arm_group_label>DAIRY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control (Whey protein, vitamin D, sugar and salt)</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus using oral hypoglycemic medication

          -  Overweight (body mass index between 25 and 34.9 kg / m2)

          -  Usual intake of calcium less than 600 mg / day

          -  Level of physical activity light to moderate

          -  HbA1c above 7% or fasting glucose above 130 mg / dl

        Exclusion Criteria:

          -  Smoking

          -  Use of calcium, vitamin D, magnesium, zinc, chromium, copper supplements or medication
             affecting the metabolism of these micronutrients,

          -  Use of drugs, herbs or diets that reduce appetite and body weight

          -  Estrogen replacement

          -  Gain or loss of at least 5 kg in the last 3 months

          -  Recent change in the level of physical activity

          -  Aversion or intolerance to food provided in the study

          -  Alcohol consumption of more than 2 doses / day (more than 50g ethanol / day)

          -  Eating disorders

          -  Endocrine disease, renal disease, hepatic disease or malabsorption syndrome that
             alters calcium metabolism

          -  History of recurrent nephrolithiasis

          -  Caffeine consumption of&gt; 300 mg / day

          -  Pregnancy, lactation or postmenopausal

          -  Anemia

          -  Cardiovascular, infectious, inflammatory, thyroid, liver, kidney or intestinal disease

          -  Use of anti-inflammatory, antacids, antibiotics and laxatives drugs

          -  Major gastrointestinal surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metabolism and body composition laboratory, Federal University of Vicosa</name>
      <address>
        <city>Viçosa</city>
        <state>Minas Gerais</state>
        <zip>36570-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <last_update_submitted>February 3, 2018</last_update_submitted>
  <last_update_submitted_qc>February 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Vicosa</investigator_affiliation>
    <investigator_full_name>Dr Junia Maria Geraldo Gomes</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

